1;Two-sided p values
1;κ (kappa) statistics with Fleiss-Cohen weights
0;ClinicalTrialsgov registration (NCT03541174)
1;Repeated-measures analysis
1;Bootstrapped (Cluster Resampling with Replacement) 95% CIs
1;Score method
1;Linear multivariable regression model
1;Sample size determination for power (90% power, 72% power)
1;Kaplan-Meier curves
1;Weighted binomial regression
1;Rubin’s rules
1;Bonferroni adjustment
1;Repeated-measures mixed linear model
1;Least squares regression
0;SAS software, version 9.4
1;Wilcoxon rank-sum test
1;Kaplan-Meier product limit estimator
1;Adjustment for confounders (region of residence, place of birth, calendar time)
0;Medical Dictionary for Regulatory Activities
1;Intention-to-treat analysis
0;Mean (SD) presentation
1;Intention-to-treat principle for statistical analysis
1;Two-sided test
1;Log-binomial regression
1;Type I error rate consideration
1;Stratified analyses
1;Random effects (random intercept)
1;Sub-distribution hazard ratio
0;R software
1;χ² test for trend
0;Use of R software for statistical computing
1;Intraclass Correlation Coefficient
0;Publication rate calculation
1;95% Confidence Intervals (CIs)
0;Co-morbidity assessment
0;Hazard rate reduction
1;Clopper-Pearson method
0;Bivalirudin
1;Trial sequential analysis
1;Multiple linear regression
1;Cause-specific hazard model
1;Predictive mean matching
1;Dichotomous outcome analysis
1;Categorical variables as absolute and relative frequencies
1;Propensity score weighting
1;Random effects model (DerSimonian and Laird)
1;Adjustment for stratification variables
1;Log relative risk (RR) estimation
1;Bayesian random effects meta-analysis
1;Multivariate Normal Distribution
0;Best-case and Worst-case Scenarios
1;P value significance testing
1;Adjusted Cox proportional-hazards models
1;Complete-case analysis
0;Trial sequential analysis software
0;Premature discontinuation
1;Sample-size calculation
0;Use of R (version 3 6 2)
1;Student’s t-test
0;R statistical computing system (used for analyses)
0;Contrast statements
1;Log(–log) plots
0;Re-analysis of eGFR data
1;Relative risks
1;Hierarchical testing procedure
1;Modified per-protocol analysis
1;Statistical significance testing (P value)
0;Graphical illustration (adjusted and weighted prevalence)
1;Common odds ratio
1;Autoregressive(1) covariance structure
0;Safety population (participants who received at least one dose of the study drug)
1;Multiple imputation
0;Data collection
0;SAS software (version 9.4) for statistical analysis
1;Markov chain Monte Carlo sampling
1;Analysis of variance with primary care physicians
0;Standardisation across trials
1;McNemar’s test
0;Overdose control principle
1;Median
1;Time-varying covariate
1;Non-inferiority analysis
1;Maximum likelihood estimation
1;Overlap weights
1;Descriptive analyses
1;Power Calculations
1;Recurrent event analysis
1;Two-sample t-test
1;Power calculations
0;Predefined statistical analysis plan
1;Continuous variable analysis (income-to-poverty ratio)
0;Sensitivity
1;Sensitivity analyses
1;Centile based 95% credible intervals
0;Use of SAS software
0;SAS software (version 9.4) usage for statistical analysis
1;Random effects
0;too small for meaningful comparison.
1;Gelman-Rubin diagnostic
1;Elixhauser comorbidity adjustment
1;Kaplan-Meier plots
1;Negative predictive value
0;Intention-to-treat approach
1;P value correction (for interim analyses)
0;Treatment effect
1;Profile Likelihood Method
1;Standardization of results
1;Interaction terms in regression
1;Generalized-estimating-equations model
1;Log-transformed Cmax and AUC (Area Under the Curve) for dose-normalized geometric means
0;Patients who received any dose of study medication
1;Two-sided tests
0;virus infection. During the analysis, data from the five
1;Point estimates with 95% confidence intervals
0;Reliability assessment (using ThinkCheckSubmit checklist)
0;Quintile classification
1;Proportional-odds logistic-regression model for ordered categorical data
1;Ageand sex-adjusted rates calculation
1;CKD-EPI 2009 equation
0;deidentified data are presented to avoid deductive
1;Multiple imputation methods
0;Percentage calculation
0;SAS Enterprise Guide software
0;Efficacy estimand for pharmacodynamic measures
1;Modified continual reassessment methods
1;Two-sided P value
1;Adjusted mean (SE) presentation
1;Heterogeneity Tests
1;Sociodemographic characteristic adjustment
1;Incidence rate ratio
1;Hazard ratio
1;Between-participant main effects
1;Cox-Stuart trend test
1;Random effect adjustment
1;Firth logistic regression
1;Covariance matrix
1;Primary composite outcome
1;Frequentist approach
1;Validly randomly assigned population analysis
1;Independent correlation structure
1;Reporting of two-sided 96.6% confidence intervals
1;Censored data
1;Descriptive statistics
1;Covariate inclusion
0;Data were analysed using SPSS software (version 28) and
0;Use of statistical software (STATA, version 17.0)
1;Power analysis
1;Laplace approximation
1;Interaction term testing for non-proportionality of hazards
1;Exploratory analyses
1;Cochran–Mantel–Haenszel test
1;Positive predictive value
0;Percentage of manuscripts with ≥50% editor agreement
1;Logistic regression
1;Forest plot construction
0;Ranking based on mean scores
0;Hierarchical testing strategy
0;Face, Legs, Activity, Cry, Consolability scale (FLACC-R)
1;Mean and standard deviation
1;Poisson regression model with robust standard errors
1;van Elteren’s test
1;Further adjustment for body mass index, muscle strength, and cardiorespiratory exercise capacity
1;Distribution description
1;P-value determination for statistical significance
1;Prespecified subgroup analysis
1;Design effect accounting for cluster randomized controlled trials
1;Mantel-Haenszel weights
1;Multiplicity adjustment
1;Pharmacokinetic dose proportionality analysis
1;Proportional contribution estimation
1;Bayesian information criterion
1;Inverse-variance-weighted averages
1;Multivariable quantile regression
1;Unstructured covariance matrix
1;Point estimates
1;Missing-at-random assumption
1;Inverse probability of attrition weight (IPAW)
1;Substitution rules
1;Mean or mode imputation
1;Adjusted risk ratio [RR]
0;Data safety and monitoring committee
0;Descriptive analysis
0;Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach
1;Kaplan-Meier curve
1;Proc MIANALYZE in SAS
1;Log-rank test (stratified and unweighted)
0;Inclusion criteria
1;Interaction Parameters
0;As-treated analysis
1;Proportion assessment
1;95% confidence intervals
1;Two-sided significance level
1;Constrained longitudinal data analysis (cLDA)
1;Fixed effects (race and ethnicity, sex, state of residence, year)
1;Two-group continuity corrected chi-square test
1;Missing values
1;Unstructured Covariance Structure
1;Design Effect
1;Effect size
1;Meta-regression
0;As-treated population analysis
1;Tests of between-study heterogeneity
0;Use of R statistical software
0;Baseline rate
1;Cox proportional hazards models
1;Mixed-model analytic approach
0;Evaluation of safety, pharmacokinetic, and pharmacodynamic parameters
1;Normal distributional assumption
1;ANCOVA (Analysis of Covariance)
1;Weighting by inverse standard deviation
1;Type I error consideration
1;Two-group t-test with a two-sided significance level
1;Generalized linear model for binomial outcome with identity function
1;Type I error (alpha)
1;Bootstrap confidence intervals
1;t test
1;Correlation structures
1;Prespecified tests for superiority
1;Clustering within participants
1;Risk Ratio (Relative Effect Measure)
1;Fine and Gray model for time-to-event data
0;Key secondary endpoint
1;Linear mixed model with random coefficients
1;Percentage of maximum possible method
1;Linear regression models
1;T tests
1;Repeated-measures mixed-effects linear regression model
0;Demographic comparison
1;Harmonic mean of person-time years
1;High-dimensional propensity-score algorithm
0;SAS software (version 9.4) usage
1;Clustering of standard errors
0;Protocol deviations
1;t-tests
1;Stratified analysis (by Journal Citation Reports quartile)
1;Confidence interval calculation
1;Generalized linear model for binomial outcome with log-link function
1;2-sample test of proportions
1;Normal-normal hierarchical models
1;Imputation of missing data
1;Sample size estimation
1;Cluster Size Sample Size Scenarios
1;Half-SD formula
1;Cumulative incidence functions
0;Modified intention-to-treat population
1;Imputation for missing data
0;Independent data monitoring committee interim analyses
1;E-value assessment
1;Poisson regression
1;Flexible parametric survival model
1;I² statistic for heterogeneity assessment
1;Efficacy analyses
1;χ² test (Chi-squared test)
1;Relative risk comparison
1;Bayesian logistic-regression model
1;Non-informative priors for mean effects
1;Hazard ratio calculation
1;Restricted cubic splines
1;Sample size calculation
1;Adjustment for sampling survey weights
1;Alpha-spending criteria
1;Multilevel Linear Mixed Model
1;Kaplan–Meier plots
1;Sample size determination
1;Binary logistic regression
1;Confidence intervals (95% confidence interval)
1;Ordinal logistic-regression model
0;Prespecified subgroups
1;Cox-proportional hazards model
1;Hierarchical Condition Category risk scoring
1;Within-group standard deviation (SD)
1;Estimation of SpO2:FiO2 ratios from PaO2:FiO2 ratios
1;Generalized estimating equations
1;Compound symmetry covariance structure
1;Weighting for national representation and nonresponse bias
1;Funnel plots
1;Cox regression model (stratified)
1;Subgroup-by-trial-group interactions
1;Ranking based on median scores
1;Modified generalized estimating equation analyses
1;Summation of scores across tests
1;Proportional hazards assumption
1;Joinpoint regression
0;Use of ICD codes for outcome assessment
1;Post hoc analyses
0;Analysis of secondary supportive end points
1;Descriptive statistics (counts and percentages, medians and IQRs)
1;Mixed-model repeated-measure analyses
1;Covariate inclusion in analyses
1;Akaike information criterion
1;Linear Regression
1;Conditional Logistic Regression
0;Crossover consideration
1;Pattern-mixture models
1;Intraclass correlation coefficient
0;of people assigned female at birth
0;Stata software usage
1;Natural logarithmic link function
1;Schoenfeld residual plots
1;descriptive statistics were reported. Aggregate and
1;Multivariable generalized estimating equations
1;Bayesian analyses
1;Analysis of covariance (ANCOVA)
0;SAS (Statistical Analysis System)
0;Adjustment for randomization site
1;2-sided α (alpha) level
1;Fisher exact test
1;Comparative analyses
1;Standardized mean differences
0;Equal weighting of tests in scoring process
1;2 × 2 factorial design analysis
1;Bivariate binomial random effects meta-analysis
1;Model-based analysis
1;Mean percentage calculation
1;Sensitivity analysis
1;Agresti formula for confidence interval
0;Software utilization (SAS software, version 9.4)
0;Cluster sizes
0;Prespecified Subgroup Analyses
1;Fisher's exact test
0;Matching (Case-control matching)
0;Use of SAS (version 9 4)
1;Sensitivity analysis with censoring
1;Mann-Whitney odds
0;Analysis of exploratory end points
1;Trend analysis
1;2-tailed P value
0;Hospital fixed effects
1;Fixed effects modeling
1;Standardised Residuals
1;Mediator analysis (as planned, later modified)
0;Per-protocol population
1;Logistic-regression models
0;Visual Analog Scale (VAS)
1;MDRD equation
1;Quantitative bias analyses
1;Linear regression
1;Randomization
1;Confidence intervals (95% CIs)
1;χ² test
1;Monte Carlo permutation method
1;Model assumptions
1;Interaction testing
1;Range
1;Repeated measures analysis
1;Regression-switching approach
1;Cluster randomized design
1;Time-to-first-event analysis
1;Nonparametric ANCOVA
1;Kruskal-Wallis rank sum test
1;Multiple comparisons analysis
1;Specificity
0;Citations analysis (overall and stratified by quartile)
1;Subgroup analysis
1;Hazard ratio estimation
1;Interaction effects
1;Rate of outcome events per 1000 patient-years
1;Power analysis for detecting differences in means and standard deviations
1;Generalised linear mixed model
1;Identity link function
0;disclosure of the identities of individuals with monkeypox
1;Skindex-29 score analysis
1;Kaplan–Meier method
1;Mann-Whitney-Wilcoxon test
1;Multivariable logistic regression
1;Missing data imputation
1;Linear mixed models
1;Data collapsing
1;Mean differences with 95% confidence intervals
1;Modified intention-to-treat (mITT) analysis
0;non-binary individuals assigned female at birth were
1;Incidence
1;Estimation of absolute benefits and harms
1;Two-sided 95% confidence interval
1;Prespecified adjustment for covariate
1;Bootstrapping
1;Complier average causal effect
1;Full analysis set
1;Model-based imputation
1;Farrington-Manning test
1;Calculation of 95% confidence intervals
1;Adjusted risk difference
1;Odds ratios with 95% confidence intervals
1;Sensitivity analysis for albuminuria levels
1;Aggregate data analysis
0;Registration of the study at ClinicalTrialsgov, NCT04143802
1;Adjustment for covariates in models
1;Aggregate measures analysis
1;Assessment of Schoenfeld residuals
1;Deviations from the missing-at-random assumption
1;Interaction term analysis
1;Imputation
1;Key secondary outcome
1;Adjusted Mean Differences
1;Wald-type approximate 95% confidence intervals
1;Covariate adjustment
0;Determination of best biscuit based on lowest overall score
1;Categorical analysis
1;Assessment of proportionality using log-minus-log plots
1;One-sided significance level
1;Multiple imputation for missing values
1;1-sided 95% Confidence Interval (CI)
1;Two-sided testing
1;Repeated-measures Poisson regression
1;Adjusted mean comparisons
1;Sensitivity Analyses
1;Win ratio (Generalized odds ratio)
0;EQ-5D-5L score analysis
1;Post hoc subset analyses
1;Pattern mixture models
1;Rubin's algorithm for multiple imputation
1;Confidence intervals
0;Certainty of evidence classification
0;Geometric mean presentation
0;Landmark approach
1;Pearson correlations
1;Multiplicity
1;Two-sided Tests
1;χ2 (Chi-square) test
1;Hazard ratio assumption revision
1;Standard deviation
1;Type I error consideration due to multiple comparisons
1;Interim analyses
1;Bonferroni correction
0;Forest plots
1;Hierarchical analysis of endpoints
1;Odds ratio calculation
1;Cause-specific mortality assessment
1;t tests
1;Within-participants effects
1;Use of SAS version 94 for data analysis
0;Continuous data
1;STATA for statistical analysis
1;Competing-risk model
1;Rate ratio estimation
1;Coefficient estimation
1;Generalised additive models
1;Two-sided significance level setting
1;Doubly robust weighted least squares estimator
1;Absolute values and change from baseline analysis
1;Group comparison
1;Treatment of skewed data
1;Unadjusted linear mixed model
1;Fully conditional specification imputation
1;Kryger Jensen and Lange test
1;Treatment of ordinal variables as continuous
1;Modified intention-to-treat analysis
1;Chained equations
1;Exact McNemar’s test
1;Confidence interval (CI) estimation
1;Summary receiver operator characteristic (ROC) curves
1;Per-protocol Analysis
1;Negative binomial model
1;Hartung-Knapp-Sidik-Jonkman confidence interval correction
0;Ranking creation
0;Maximum of diagnosis indicator
0;Adjustment for stress resilience and cognitive ability scores
1;Relative difference estimation
1;Estimation from median and interquartile range
1;SAS (Statistical Analysis Software) for data analysis
1;Progression-free survival percentage comparison
1;Clustering
1;Effect sizes with 95% confidence intervals
1;Geometric mean concentrations and ratios
0;Median and IQR (Interquartile Range)
0;Mean frequency function display
1;95% CIs (Confidence Intervals)
1;Bias-corrected and accelerated bootstrap resampling
1;Two-tailed alpha level
1;Sample size determination for phase 1 studies
1;Unadjusted log-rank tests
1;Two-sided tests of superiority
1;Random walk Metropolis-Hastings algorithm with Gibbs updates
1;Bayesian analysis
1;One-way ANOVA Method
1;Number needed to treat
1;Kaplan-Meier method
1;Use of R software
0;Significance testing
0;Cut-off based analysis (>30 and >50 citations)
1;Mann-Whitney U test
1;Contrast analysis
0;Deidentified data presentation
1;Confidence interval (CI) calculation
1;Noninferiority margin determination
0;Primary endpoint
1;Clustered Design
1;Score test for proportionality assumption
1;Fisher’s exact test
1;Least-squares means (LSMs) and 90% confidence intervals (CIs)
1;Reporting of two-sided 95% confidence intervals
1;Time-to-first-event rates
1;Fixed effects
0;Loss to follow-up consideration
1;Rubin’s formula for confidence intervals
1;Competing-risk events
1;Testing of proportional hazards using Schoenfeld residuals
1;Relative risks estimation
1;Linear regression (for QTcF value assessment)
1;Post hoc analysis
0;Citation analysis within the first two years after publication
1;Repeated measures
1;Adjusted mean between-group difference
0;Time elapsed calculation (between submission and publication, and between publication and retraction)
1;Mixed models for repeated measures
1;Modified ridit scores
1;Prespecified subgroup analyses
1;Cox proportional hazards model
1;Two-sided χ² test
1;Modified Poisson Regression Model
1;Estimated relative risk
1;Alpha level (significance level)
1;Intention-to-treat (ITT) analysis
1;Sandwich estimator
0;Pharmacokinetic and pharmacodynamic population
1;Calculation of relative risks (RR) with 95% confidence intervals (CIs)
1;Risk difference estimation
1;Cox model
1;Multilevel Log-binomial Regression Models
1;Finkelstein-Schoenfeld hierarchical composite endpoint
1;P value determination
1;Poisson distribution
1;Logistic regression with logit link
1;Markov chain Monte Carlo method
1;Fully conditional specification
1;Time-to-event outcomes
1;Covariates
1;Repeated measures design
1;Statistical analyses
1;Pairwise comparisons
1;Leave-one-out site analysis
0;Stratification according to randomization
1;Statistical analysis
1;Use of “survival” R package
0;Treatment group
1;Absolute risk reduction
0;Stratification by factors (VA health care system)
1;Exact binomial test
1;Cluster-level summaries
1;Per-protocol analyses
1;Informative priors for heterogeneity
1;Binomial confidence intervals
1;Robust Standard Errors
1;Power calculation
1;Cox proportional-hazards model
1;Wald standard error
0;Definition-based outcome assessment
1;Empirical Bayes shrinkage estimator
1;Two-tailed t-test
1;Dichotomisation of responses
1;Hazard ratios (HR)
1;Safety analysis assuming binomial distributions
1;Cubic splines
1;Propensity scores
1;Standard χ² tests for heterogeneity
1;Cochran-Mantel-Haenszel method
1;Intention-to-treat principle
1;Last observation carried forward (LOCF)
1;Mean ± standard deviation
1;Unconditional logistic regression
1;Use of “epitools” R package
0;grouped with data from cis women (forming a category
1;Joint models
1;Cox regression analysis
1;Exploratory analysis
1;Cox models
1;Covariates adjustment
1;Frequency calculation
1;Age standardisation
1;Mixed model
1;Predefined subgroup analysis
1;Mean
1;Categorical variables
1;Confidence intervals (CIs)
1;Interim analysis
0;Time-to-event analysis
0;Military Conscription Register analysis
1;Meta-analysis
1;Egger’s test
1;Event rate calculation
1;Two-tailed tests
1;χ2 tests
1;Estimation of mean and SD from median and IQR
1;Logistic regression for binary outcomes
1;Unpaired t-tests
1;Proc GENMOD in SAS
1;Mixed-effects linear regression modeling
1;Unstructured covariance structure and compound symmetric structure in statistical modeling
1;Two-sided alpha level
1;Composite outcome scoring
1;Intention to treat
1;χ2 test
0;SAS version 94
0;Drop-out rate
1;Type I error rate
0;No adjustment for multiple comparisons
1;Generalised linear mixed models
1;Kaplan-Meier estimates
1;Coefficient of variation
1;Marginal model for repeated measures analyses
1;Log-rank test
1;Restricted maximum likelihood approach
1;Per-protocol analysis
1;Generalized estimating equation (GEE) model
0;Supportive analyses
0;Exclusion criteria
0;Heparin group
1;Absolute number and relative frequency calculation
1;Summary data extraction
1;Average treatment effect estimation
1;Subgroup analyses
0;Consensus discussion
1;Proc MI in SAS
1;Relative risks with 95% confidence intervals
1;Median and interquartile range calculation
0;Diuretic or antihypertensive rescue medication
